|Bid||0.00 x 1800|
|Ask||54.99 x 1800|
|Day's Range||53.80 - 58.74|
|52 Week Range||30.15 - 64.94|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.31|
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of 3,375,527 shares of its common stock for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT. In addition, GBT has granted the underwriter a 30-day option to purchase up to an additional $30.0 million of additional shares of common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering. In addition, GBT has granted the underwriter a 30-day option to purchase up to approximately $30.0 million in shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. GBT intends to use the net proceeds from the offering and its existing capital resources to fund its clinical development of voxelotor for the treatment of sickle cell disease, including its ongoing clinical studies, its activities in preparation for the potential commercial launch of voxelotor, if approved by the U.S. Food and Drug Administration, and future clinical trials of voxelotor and other product candidates that GBT may elect to pursue, including inclacumab, and to fund its other research and development activities and for working capital and general corporate purposes. GBT may also use a portion of the net proceeds to in-license, acquire or invest in new business, technology or assets, although it has no material agreements, commitments or understandings in place.
If you're interested in Global Blood Therapeutics, Inc. (NASDAQ:GBT), then you might want to consider its beta (a...
Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease (SCD). The findings from 274 adolescents and adults treated with voxelotor showed the HOPE Study met its primary endpoint of an improvement in hemoglobin greater than 1 g/dL at 24 weeks with voxelotor 1500 mg compared with placebo, with a favorable safety and tolerability profile.
Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif., June 10, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five nonprofit organizations have been awarded more than.
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SOUTH SAN FRANCISCO, Calif., June 07, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2019, the compensation committee of GBT’s.
Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort to be Presented During Presidential Symposium New Drug Application (NDA) Submission Planned for Voxelotor.
The South San Francisco, California-based company said it had a loss of 87 cents per share. The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment ...
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the first.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Global Blood Therapeutics, Inc.'s (NASDAQ:GBT): Global Blood Therapeutics, Inc., a clinical-sta...
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
SOUTH SAN FRANCISCO, Calif., April 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if theRead More...
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.